Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has signed an agreement with Timser Group, a pharmaceutical company focused...
A recent British Journal of Cancer evaluated the real-world safety and efficacy of sacituzumab govitecan (SG) against metastatic triple-negative breast cancer (mTNBC). Study: Real world study of sacituzumab govitecan...